Moderna (MRNA) Cash from Financing Activities (2018 - 2026)

Moderna (MRNA) has 9 years of Cash from Financing Activities data on file, last reported at $17.0 million in Q1 2026.

• On a quarterly basis, Cash from Financing Activities rose 325.0% year-over-year to $17.0 million in Q1 2026; TTM through Mar 2026 was $606.0 million, a 1217.39% increase from a year earlier, with the FY2025 full-year figure at $593.0 million, up 958.93% from the prior year.
• Cash from Financing Activities for Q1 2026 stood at $17.0 million, down from $581.0 million in the prior quarter.
• Over the last five years, Cash from Financing Activities for MRNA reached as high as $581.0 million in Q4 2025 and fell as low as -$1.3 billion in Q2 2022.
• Historically, Cash from Financing Activities has averaged -$244.6 million across 5 years, with a median of -$3.0 million in 2024.
• Across the five-year window, Cash from Financing Activities slumped 51950.0% in 2022 and jumped 19466.67% in 2025, its largest moves.
• Year by year, Cash from Financing Activities stood at -$438.0 million in 2022, then soared by 75.11% to -$109.0 million in 2023, then jumped by 97.25% to -$3.0 million in 2024, then soared by 19466.67% to $581.0 million in 2025, then tumbled by 97.07% to $17.0 million in 2026.
• Per Business Quant data, the three most recent Cash from Financing Activities figures were $17.0 million in Q1 2026, $581.0 million in Q4 2025, and -$1.0 million in Q3 2025.